Haemonetics Corporation announced that the VASCADE MVP Venous Vascular Closure System is now the first and only vascular closure device to receive FDA indication for same-day discharge following atrial fibrillation (AF) ablation. The Same-Day Discharge labeling was granted following the conclusion of the first two registries in the AMBULATE Same-Day Discharge (SDD) clinical study series, which evaluated the safety and efficacy of using VASCADE MVP to facilitate same-day discharge of AF ablation patients. As of July 2021, Cardiva Medical Inc., an industry-leading manufacturer of vascular closure systems acquired by Haemonetics earlier this year, has completed three of its four planned registries in the AMBULATE Same-Day Discharge Clinical Study Series. The first study was a multi-center retrospective study that enrolled 497 subjects across four U.S. centers, and the second study was a prospective, multi-center, single-arm study, referred to as SDD #1. SDD #1 enrolled 151 paroxysmal AF patients at eight U.S. centers under the direction of 27 investigators. The most recent study, AMBULATE Same-Day Discharge #2, was a multi-center, prospective, single-arm study that enrolled 203 persistent AF patients at 13 U.S. centers under the direction of 37 investigators. The studies demonstrated; Retrospective Study " 99.4% of subjects treated for AF with venous closure using the VASCADE MVP were sent home the same day without additional intervention post-discharge, SDD #1- 98.6% of subjects treated for paroxysmal AF with venous closure using the VASCADE MVP were sent home the same day without additional intervention post-discharge and SDD #2: 99.5% of subjects treated for persistent AF with venous closure using the VASCADE MVP were sent home the same day without additional intervention post-discharge.